provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
HomeDrugsRituxan

Is There a Biosimilar to Rituximab? Yes, Here Are 3 Rituximab Biosimilars You Should Know

Rachel Feaster, PharmD, BCOP, BCPSAlyssa Billingsley, PharmD
Published on February 1, 2023

Key takeaways:

  • Rituximab (Rituxan) currently has three biosimilars available: rituximab-abbs (Truxima), rituximab-pvvr (Ruxience), and rituximab-arrx (Riabni).

  • Rituximab biosimilars are highly similar to Rituxan. They have the same expected side effects and benefits. However, unlike Rituxan, the biosimilars aren’t FDA approved for children or a condition called pemphigus vulgaris.

  • Your healthcare provider and insurance status will likely determine the best rituximab product for you. Choosing the best rituximab biosimilar is mostly driven by savings opportunities for you and your care team.

Access savings on related medications

A needle has been injected into a vial of medication.
Toshe_O/E+ via Getty Images

Picture this — you walk into the infusion clinic to start a medication called rituximab (Rituxan). You’re approved by insurance and educated on medication side effects and expectations; you’re good to go. As the nurse hangs the bag, you hear them say a different medication name. “Are you sure you haven’t made a mistake?” you ask. It’s not a mistake, the nurse explains. That’s because you are receiving a rituximab biosimilar.

But what is a biosimilar? Biosimilars are biologic medications that are “highly similar” to an original FDA-approved medication. Biologics themselves are complex medications that come from living sources. And while they aren’t exactly the same, biosimilars are meant to be just as effective and safe as the original biologic. 

Rituxan has three biosimilars: rituximab-abbs (Truxima), rituximab-pvvr (Ruxience), and rituximab-arrx (Riabni). We’ll discuss why rituximab biosimilars exist and whether there are any major differences between them.

SPECIAL OFFER

An interchangeable biosimilar to Humira® for 92% less

Introducing Adalimumab-adbm, an autoimmune medication that is the first-ever FDA-approved interchangeable biosimilar to Humira®. Get it for 92% less than the Humira® list price.

Woman smiling at camera doing workout morning routine outdoors.
DisobeyArt/iStock via Getty Images Plus

What is rituximab?

Rituximab (Rituxan) is a monoclonal antibody medication. It attaches to and marks certain white blood cells (B cells) for destruction. B cells are involved in development of certain blood cancers and autoimmune conditions.

Rituximab is administered into your vein. How often it’s given depends on what it’s being used for — this typically ranges from weekly to monthly. It’s approved to treat several health conditions in both kids and adults.

Approved uses for adults

Approved uses for children

Blood cancers

• Certain Non-Hodgkin’s lymphomas (NHL)
Chronic lymphocytic leukemia (CLL)

• Certain Non-Hodgkin’s lymphomas

Autoimmune disorders

Rheumatoid arthritis (RA)
• Pemphigus vulgaris
• Wegener’s granulomatosis
• Microscopic polyangiitis

• Wegener’s granulomatosis
• Microscopic polyangiitis

Rituximab vs. rituximab biosimilars

Why do biosimilars exist? The main reason is cost and medication accessibility. Adding biosimilars creates competition among manufacturers, which ultimately drives prices down. This helps make biologic medications like rituximab more affordable

Many people think that biosimilars are the same as generics. This is not technically true. Generics are exact copies of the original brand-name medication. Generics are also made chemically, so it’s easier to copy them and produce them in bulk. Biosimilars are made from natural and living sources, so it’s impossible to copy them exactly. This means that biosimilars may have slight differences from the original medication. But do these differences mean anything?

Not really. Biosimilars still have to undergo rigorous quality testing, just like generics. Biosimilar manufacturers must also provide information to the FDA that proves their medication is just as effective and safe as the original product.

The main difference between Rituxan and its biosimilars is their FDA-approved indications. All approved uses are the same, except the biosimilars aren’t approved for pemphigus vulgaris. The biosimilars aren’t approved for use in children, either.

Now, let’s discuss each biosimilar more specifically.

1. Truxima

Rituximab-abbs (Truxima) became the first FDA-approved rituximab biosimilar in 2018. At first, it was only approved for NHL. But by mid-2020, its indications expanded to CLL, RA, and Wegener’s granulomatosis/microscopic polyangiitis. 

Various studies support these approved uses. For instance, Truxima’s approval for NHL and CLL was based on two studies comparing Truxima to Rituxan in people with a slow growing type of NHL.

The first study included people with advanced cancer being treated with both rituximab and chemotherapy. After 6 months, the cancer either shrank or disappeared in 97% of people receiving Truxima and 93% receiving Rituxan. Truxima was considered non-inferior to Rituxan, meaning it wasn’t any worse.

The second study was conducted in people with less advanced cancer being treated with rituximab alone. After 7 months, the cancer either shrank or disappeared in 83% of people receiving Truxima and 81% of people receiving Rituxan. Truxima was considered equivalent to Rituxan. 

2. Ruxience

Rituximab-pvvr (Ruxience) became the second FDA-approved rituximab biosimilar in 2019. Its first four uses were approved in 2019, but it became approved for RA in 2021.

Data also supports Ruxience’s approval for these health conditions. For NHL and CLL, one study compared Ruxience to MabThera (the European brand of rituximab) in people with less advanced NHL. After about 6 months, the cancer either shrank or disappeared in 76% of people receiving Ruxience compared to 71% with MabThera. Ruxience was considered equivalent to MabThera, which itself is similar to Rituxan.

3. Riabni

Rituximab-arrx (Riabni) became the third FDA-approved rituximab biosimilar in 2020. It has the same approved uses as Truxima and Ruxience; its approval for RA just came through in 2022

Riabni is also backed by supporting data. For example, one study compared Riabni to Rituxan in people living with NHL. After 7 months, the cancer either shrank or disappeared in 78% of people receiving Riabni and 70% of people receiving Rituxan. Riabni was considered equivalent to Rituxan.

For all three biosimilars, there were no major differences in side effects or safety concerns in the studies mentioned above.

How to choose the best rituximab biosimilar

Rituximab biosimilars are dosed and given the exact same way as Rituxan. And since there are no major differences in side effects or how well they work, the best choice generally comes down to affordability. The product you’ll receive often depends on your insurance status and what’s available to your healthcare provider.

The two exceptions are with pemphigus vulgaris and children. If you have pemphigus vulgaris or have a child being treated with rituximab, you’ll likely need to stick with Rituxan. Biosimilars are not approved for these scenarios.

Otherwise, if you do have the option to choose, check with your insurance company (if applicable) to see what their preferred product is. This can help limit what you pay out of pocket. If you have a high copay, all rituximab products have copay card options to help you access them at a lower cost.

Other options include finding funding from a charitable foundation, such as the Patient Access Network Foundation. You can also apply for the manufacturer’s patient assistance program to see if you qualify for free medication.

Switching between rituximab products

One area that’s less clear is whether it’s OK to switch from Rituxan to one of its biosimilars (or vice versa). 

Some people worry about how safe it is to switch between rituximab products. After all, rituximab biosimilars are not officially designated as being interchangeable with Rituxan. This means that manufacturers have not taken additional steps to prove that you can switch back and forth between products without issue.

However, in reality, your healthcare provider may still decide to switch between products. This will be based on their experience, what they have available at their institution, and available safety data.

For instance, studies in NHL and RA suggest that it’s safe to switch from Rituxan to Truxima. Researchers have also tested to see if it’s more likely for your body to react poorly to Truxima, Ruxience, or Riabni compared to Rituxan. These studies haven’t found any notable differences in the likelihood of experiencing a bad reaction.

The bottom line

Rituxan is a biologic medication used for the treatment of certain blood cancers and autoimmune conditions. Three rituximab biosimilars are available to help increase access to this treatment: Truxima, Ruxience, and Riabni. These biosimilars have all the same approved indications as Rituxan, except for use in children and pemphigus vulgaris. They are expected to have the same effectiveness and safety as Rituxan.

Choosing the right rituximab product depends on cost, insurance status, and product availability.

why trust our exports reliability shield

Why trust our experts?

Rachel Feaster, PharmD, BCOP, BCPS
Rachel Feaster has over 10 years of professional experience in ambulatory, inpatient, pharmacogenomics, and oncology care. She is board certified in oncology and pharmacotherapy.
Joshua Murdock, PharmD, BCBBS
Joshua Murdock, PharmD, BCBBS, is a licensed pharmacist in Arizona, Colorado, and Rhode Island. He has worked in the pharmacy industry for more than 10 years and currently serves as a pharmacy editor for GoodRx.
Alyssa Billingsley, PharmD
Alyssa Billingsley, PharmD, is the director of pharmacy content for GoodRx. She has over a decade of experience as a pharmacist and has worked in clinical, academic, and administrative roles.
View All References (19)

Genentech, Inc. (2022). Rituxan [package insert].

Kaufman, M. B. (2022). FDA approves Riabni, a rituxumab biosimilar, to treat patients with RA. The Rheumatologist.

Kim, W. S., et al. (2017). Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: A randomised, double-blind, parallel-group, non-inferiority phase 3 trial. The Lancet Haematology

Kwak, L. W., et al. (2022). Efficacy and safety of CT-P10 versus rituximab in untreated low-tumor-burden follicular lymphoma: Final results of a randomized phase III study. Clinical Lymphoma, Myeloma, and Leukemia

Nahleh, Z., et al. (2022). Use of biosimilar medications in oncology. JCO Oncology Practice

National Cancer Institute. (n.d.). Non-inferiority trial.

National Cancer Institute. (2019). Monoclonal antibodies

Niederweiser, D, et al. (2020). Efficacy and safety of ABP 798: Results from the JASMINE trial in patients with follicular lymphoma in comparison with rituximab reference product. Targeted Oncology

Ogura, M., et al. (2018). Efficacy, pharmacokinetics, and safety of biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, doubled-blind, parallel-group, phase 3 trial. The Lancet Haematology

Pfizer. (2019). FDA approves Pfizer’s biosimilar Ruxience (rituximab-pvvr) for certain cancers and autoimmune conditions

Pfizer Ireland Pharmaceuticals. (2021). Ruxience [package insert]

Sharman, J. P., et al. (2020). A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with previously untreated CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL). Biodrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy

Shim, S. C., et al. (2019). Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized phase 3 trial. Rheumatology

Teva. (2022). Truxima (rituximab-abbs) [package insert].

U.S. Food and Drug Administration. (n.d.). Biosimilars: Are they the same quality?

U.S. Food and Drug Administration. (2018). FDA approves first biosimilar for treatment of adult patients with non-hodgkin’s lymphoma.

U.S. Food and Drug Administration. (2022). Biosimilar basics for patients

U.S. Food and Drug Administration Center for Drug Evaluation and Research. (2018). Application number: 761088Orig1s000. Summary review.

U.S. Food and Drug Administration Center for Drug Evaluation and Research. (2020). Application number: 761140Orig1s000. Multi-discipline review.

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

Was this page helpful?

Subscribe and save.

Get prescription saving tips and more from GoodRx Health. Enter your email to sign up.

By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.